A7RC peptide modified paclitaxel liposomes dually target breast cancer.
暂无分享,去创建一个
Ying Liu | Ying Ruan | Jingyan Cao | Chunlan Zhou | Yan Yu | Y. Liu | Qun Wang | Haisheng Peng | Ran Wang | Yan Yu | Chunlan Zhou | Qun Wang | Y. Ruan | Haisheng Peng | Ran Wang | Ning Gao | Minghui Li | Xuyu Tian | Weili Yang | Guangtian Wang | Xiaoying Liu | Shukun Tang | Guangyu Sun | Jingyan Cao | Xiaoying Liu | Shukun Tang | Weili Yang | Guangyu Sun | Minghui Li | Guangtian Wang | N. Gao | Xuyu Tian
[1] Vicente Micol,et al. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells , 2013, Breast Cancer Research and Treatment.
[2] D. Leong,et al. The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. , 2014, Biomaterials.
[3] J. Benoit,et al. Brain targeting using novel lipid nanovectors. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[4] Jaroslav Turánek,et al. Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[5] B. Leyland-Jones,et al. Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Stephen S. Taylor,et al. How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.
[7] M. Crépin,et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.
[8] Judy Mak,et al. Neuropilin‐1 expression in cancer and development , 2012, The Journal of pathology.
[9] C. M. Paleos,et al. Mixed Vesicles of Didodecyldimethylammonium Bromide with Recognizable Moieties at the Interface , 1996 .
[10] Lin Mei,et al. Paclitaxel drug delivery systems , 2013, Expert opinion on drug delivery.
[11] M. Tessier-Lavigne,et al. Neuropilins in Tumor Biology , 2009, Clinical Cancer Research.
[12] M. Reed,et al. Neuropilins in physiological and pathological angiogenesis , 2007, The Journal of pathology.
[13] Tianfu Wang,et al. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. , 2014, Biomaterials.
[14] Haisheng Peng,et al. Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain. , 2013, Therapeutic delivery.
[15] Ming-hui Li,et al. HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia–reperfusion injury in rats , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.
[16] D. Leong,et al. Anti-migratory and increased cytotoxic effects of novel dual drug-loaded complex hybrid micelles in triple negative breast cancer cells , 2015, Nano Research.
[17] Yan Zhang,et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. , 2011, Biomaterials.
[18] M. I. Setyawati,et al. In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. , 2015, Biomaterials.
[19] J. Choi,et al. Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. , 2014, Journal of nanoscience and nanotechnology.
[20] Ulrich Beyer,et al. Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.
[21] Say Chye Joachim Loo,et al. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin , 2013, Nature Communications.
[22] H. Brem,et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies , 2007, Expert opinion on drug safety.
[23] Zhengping Hu,et al. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[24] Ming-hui Li,et al. Liposomes modified with P-aminophenyl-α-D-mannopyranoside: a carrier for targeting cerebral functional regions in mice. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[25] Qun Wang,et al. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery , 2008, Journal of drug targeting.
[26] Neil Genzlinger. A. and Q , 2006 .
[27] Wolfgang J. Parak,et al. Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .
[28] Daming Liu,et al. Heart-targeted nanoscale drug delivery systems. , 2014, Journal of biomedical nanotechnology.
[29] Weipeng Cao,et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.
[30] J. Beijnen,et al. Liposomal drug formulations in the treatment of rheumatoid arthritis. , 2011, Molecular pharmaceutics.
[31] W. Marsden. I and J , 2012 .
[32] Hongbing Deng,et al. Functional nanoparticles in targeting glioma diagnosis and therapies. , 2014, Journal of nanoscience and nanotechnology.
[33] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[34] Y. Hasegawa,et al. Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer , 2011, Cancer Chemotherapy and Pharmacology.
[35] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[36] Qun Wang,et al. The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[37] Lena Claesson-Welsh,et al. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.
[38] S. Balasubramanian,et al. Preparation and characterization of taxane-containing liposomes. , 2005, Methods in enzymology.
[39] Franklin Peale,et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.
[40] B. Corfe,et al. Neuropilins: expression and roles in the epithelium , 2012, International journal of experimental pathology.
[41] Oku. Anticancer therapy using glucuronate modified long-circulating liposomes. , 1999, Advanced drug delivery reviews.
[42] D. Leong,et al. Probing the relevance of 3D cancer models in nanomedicine research. , 2014, Advanced drug delivery reviews.
[43] Alex L Kolodkin,et al. Neuropilin Is a Semaphorin III Receptor , 1997, Cell.
[44] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .
[45] Zhe-Sheng Chen,et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo , 2006, Cancer biology & therapy.
[46] Shay Soker,et al. Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.
[47] C. Demangel,et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.
[48] N. Charnaux,et al. Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1 , 2006, Journal of drug targeting.
[49] Y. Glinka,et al. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity , 2012, Oncotarget.
[50] R. Stephenson. A and V , 1962, The British journal of ophthalmology.
[51] Hulun Li,et al. Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy. , 2008, International journal of pharmaceutics.
[52] A. Dash,et al. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. , 2009, Critical reviews in therapeutic drug carrier systems.
[53] Yitao Wang,et al. Advances in self-assembled chitosan nanomaterials for drug delivery. , 2014, Biotechnology advances.
[54] Yun-Fei Xia,et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. , 2006, Cancer research.
[55] M. Klagsbrun,et al. Targeting endothelial and tumor cells with semaphorins , 2007, Cancer and Metastasis Reviews.
[56] A. Safavy. Recent developments in taxane drug delivery. , 2008, Current drug delivery.
[57] Tianfu Wang,et al. Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. , 2014, Journal of materials chemistry. B.
[58] Balaji Narasimhan,et al. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[59] Aaas News,et al. Book Reviews , 1893, Buffalo Medical and Surgical Journal.
[60] Feng Tian,et al. NRP-1 expression in bladder cancer and its implications for tumor progression , 2014, Tumor Biology.
[61] Ming-hui Li,et al. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers , 2012, Journal of liposome research.
[62] A. Eichmann,et al. Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos , 2008, Development.
[63] W. Zhou,et al. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes , 2010, Nanotechnology.